Addex Therapeutics - ADXN Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Addex Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADXN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXN, but not buy additional shares or sell existing shares.
View ADXN analyst ratings or view top-rated stocks.

1 brokerages have issued 1-year target prices for Addex Therapeutics' shares. Their ADXN share price forecasts range from $15.00 to $15.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 1,019.4% from the stock's current price.
View analysts price targets for ADXN or view top-rated stocks among Wall Street analysts.

Addex Therapeutics' stock was trading at $6.29 at the start of the year. Since then, ADXN shares have decreased by 78.7% and is now trading at $1.34.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 18th 2022.
View our ADXN earnings forecast.

Addex Therapeutics Ltd (NASDAQ:ADXN) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.72) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.72). The company had revenue of $0.83 million for the quarter, compared to the consensus estimate of $0.42 million. Addex Therapeutics had a negative trailing twelve-month return on equity of 123.92% and a negative net margin of 748.78%. During the same period last year, the company posted ($0.78) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Addex Therapeutics investors own include Achillion Pharmaceuticals (ACHN), Aurora Cannabis (ACB), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced Biomedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY).

Addex Therapeutics trades on the NASDAQ under the ticker symbol "ADXN."

Addex Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include OLD Mission Capital LLC (0.29%).

Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADXN stock can currently be purchased for approximately $1.34.

Addex Therapeutics (NASDAQ:ADXN) has a market capitalization of $14.58 million and generates $3.45 million in revenue each year. The company earns $-16,800,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis.

Addex Therapeutics' mailing address is CHEMIN DES AULX 12 PLAN-LES-OUATES, GENEVA V8, CH-1228. The official website for the company is www.addextherapeutics.com. The company can be reached via phone at 41-22-884-1555, via email at investor.relations@addextherapeutics.com, or via fax at 41-22-884-1556.